These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 36453228)

  • 21. Efficacy of Multi-exon Skipping Treatment in Duchenne Muscular Dystrophy Dog Model Neonates.
    Lim KRQ; Echigoya Y; Nagata T; Kuraoka M; Kobayashi M; Aoki Y; Partridge T; Maruyama R; Takeda S; Yokota T
    Mol Ther; 2019 Jan; 27(1):76-86. PubMed ID: 30448197
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Urine titin as a novel biomarker for Duchenne muscular dystrophy.
    Ishii MN; Nakashima M; Kamiguchi H; Zach N; Kuboki R; Baba R; Hirakawa T; Suzuki K; Quinton M
    Neuromuscul Disord; 2023 Apr; 33(4):302-308. PubMed ID: 36871413
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Direct Reprogramming of Human DMD Fibroblasts into Myotubes for In Vitro Evaluation of Antisense-Mediated Exon Skipping and Exons 45-55 Skipping Accompanied by Rescue of Dystrophin Expression.
    Lee JJA; Saito T; Duddy W; Takeda S; Yokota T
    Methods Mol Biol; 2018; 1828():141-150. PubMed ID: 30171539
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antisense Oligonucleotide Treatment in a Humanized Mouse Model of Duchenne Muscular Dystrophy and Highly Sensitive Detection of Dystrophin Using Western Blotting.
    Maruyama R; Yokota T
    Methods Mol Biol; 2021; 2224():203-214. PubMed ID: 33606217
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Autoimmune response and its long-term consequences after exon-skipping therapy in a Duchenne muscular dystrophy mouse model.
    Nordin JZ; Aoki Y
    J Pathol; 2019 Nov; 249(3):271-273. PubMed ID: 31322741
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term microdystrophin gene therapy is effective in a canine model of Duchenne muscular dystrophy.
    Le Guiner C; Servais L; Montus M; Larcher T; Fraysse B; Moullec S; Allais M; François V; Dutilleul M; Malerba A; Koo T; Thibaut JL; Matot B; Devaux M; Le Duff J; Deschamps JY; Barthelemy I; Blot S; Testault I; Wahbi K; Ederhy S; Martin S; Veron P; Georger C; Athanasopoulos T; Masurier C; Mingozzi F; Carlier P; Gjata B; Hogrel JY; Adjali O; Mavilio F; Voit T; Moullier P; Dickson G
    Nat Commun; 2017 Jul; 8():16105. PubMed ID: 28742067
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dystrophin quantification and clinical correlations in Becker muscular dystrophy: implications for clinical trials.
    Anthony K; Cirak S; Torelli S; Tasca G; Feng L; Arechavala-Gomeza V; Armaroli A; Guglieri M; Straathof CS; Verschuuren JJ; Aartsma-Rus A; Helderman-van den Enden P; Bushby K; Straub V; Sewry C; Ferlini A; Ricci E; Morgan JE; Muntoni F
    Brain; 2011 Dec; 134(Pt 12):3547-59. PubMed ID: 22102647
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessment of Systemic Delivery of rAAVrh74.MHCK7.micro-dystrophin in Children With Duchenne Muscular Dystrophy: A Nonrandomized Controlled Trial.
    Mendell JR; Sahenk Z; Lehman K; Nease C; Lowes LP; Miller NF; Iammarino MA; Alfano LN; Nicholl A; Al-Zaidy S; Lewis S; Church K; Shell R; Cripe LH; Potter RA; Griffin DA; Pozsgai E; Dugar A; Hogan M; Rodino-Klapac LR
    JAMA Neurol; 2020 Sep; 77(9):1122-1131. PubMed ID: 32539076
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Effect of Immunomodulatory Treatments on Anti-Dystrophin Immune Response After AAV Gene Therapy in Dystrophin Deficient mdx Mice.
    Li N; Parkes JE; Spathis R; Morales M; Mcdonald J; Kendra RM; Ott EM; Brown KJ; Lawlor MW; Nagaraju K
    J Neuromuscul Dis; 2021; 8(s2):S325-S340. PubMed ID: 34569971
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Somatic gene editing ameliorates skeletal and cardiac muscle failure in pig and human models of Duchenne muscular dystrophy.
    Moretti A; Fonteyne L; Giesert F; Hoppmann P; Meier AB; Bozoglu T; Baehr A; Schneider CM; Sinnecker D; Klett K; Fröhlich T; Rahman FA; Haufe T; Sun S; Jurisch V; Kessler B; Hinkel R; Dirschinger R; Martens E; Jilek C; Graf A; Krebs S; Santamaria G; Kurome M; Zakhartchenko V; Campbell B; Voelse K; Wolf A; Ziegler T; Reichert S; Lee S; Flenkenthaler F; Dorn T; Jeremias I; Blum H; Dendorfer A; Schnieke A; Krause S; Walter MC; Klymiuk N; Laugwitz KL; Wolf E; Wurst W; Kupatt C
    Nat Med; 2020 Feb; 26(2):207-214. PubMed ID: 31988462
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In Vitro Multiexon Skipping by Antisense PMOs in Dystrophic Dog and Exon 7-Deleted DMD Patient.
    Nakamura A; Aoki Y; Tsoumpra M; Yokota T; Takeda S
    Methods Mol Biol; 2018; 1828():151-163. PubMed ID: 30171540
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Full-length dystrophin restoration via targeted exon integration by AAV-CRISPR in a humanized mouse model of Duchenne muscular dystrophy.
    Pickar-Oliver A; Gough V; Bohning JD; Liu S; Robinson-Hamm JN; Daniels H; Majoros WH; Devlin G; Asokan A; Gersbach CA
    Mol Ther; 2021 Nov; 29(11):3243-3257. PubMed ID: 34509668
    [TBL] [Abstract][Full Text] [Related]  

  • 33. TIPE2 gene transfer with adeno-associated virus 9 ameliorates dystrophic pathology in mdx mice.
    Gao S; Lu A; Amra S; Guo P; Huard J
    Hum Mol Genet; 2019 May; 28(10):1608-1619. PubMed ID: 30608588
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intravenous infusion of an antisense oligonucleotide results in exon skipping in muscle dystrophin mRNA of Duchenne muscular dystrophy.
    Takeshima Y; Yagi M; Wada H; Ishibashi K; Nishiyama A; Kakumoto M; Sakaeda T; Saura R; Okumura K; Matsuo M
    Pediatr Res; 2006 May; 59(5):690-4. PubMed ID: 16627883
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Revertant fibres and dystrophin traces in Duchenne muscular dystrophy: implication for clinical trials.
    Arechavala-Gomeza V; Kinali M; Feng L; Guglieri M; Edge G; Main M; Hunt D; Lehovsky J; Straub V; Bushby K; Sewry CA; Morgan JE; Muntoni F
    Neuromuscul Disord; 2010 May; 20(5):295-301. PubMed ID: 20395141
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy.
    Echigoya Y; Lim KRQ; Trieu N; Bao B; Miskew Nichols B; Vila MC; Novak JS; Hara Y; Lee J; Touznik A; Mamchaoui K; Aoki Y; Takeda S; Nagaraju K; Mouly V; Maruyama R; Duddy W; Yokota T
    Mol Ther; 2017 Nov; 25(11):2561-2572. PubMed ID: 28865998
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CRISPR/Cas9-generated mouse model of Duchenne muscular dystrophy recapitulating a newly identified large 430 kb deletion in the human
    Egorova TV; Zotova ED; Reshetov DA; Polikarpova AV; Vassilieva SG; Vlodavets DV; Gavrilov AA; Ulianov SV; Buchman VL; Deykin AV
    Dis Model Mech; 2019 Apr; 12(4):. PubMed ID: 31028078
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Large in-frame 5' deletions in DMD associated with mild Duchenne muscular dystrophy: Two case reports and a review of the literature.
    Gibbs EM; Barthélémy F; Douine ED; Hardiman NC; Shieh PB; Khanlou N; Crosbie RH; Nelson SF; Miceli MC
    Neuromuscul Disord; 2019 Nov; 29(11):863-873. PubMed ID: 31672265
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dystrophin Gene-Editing Stability Is Dependent on Dystrophin Levels in Skeletal but Not Cardiac Muscles.
    Bengtsson NE; Tasfaout H; Hauschka SD; Chamberlain JS
    Mol Ther; 2021 Mar; 29(3):1070-1085. PubMed ID: 33160075
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dantrolene enhances antisense-mediated exon skipping in human and mouse models of Duchenne muscular dystrophy.
    Kendall GC; Mokhonova EI; Moran M; Sejbuk NE; Wang DW; Silva O; Wang RT; Martinez L; Lu QL; Damoiseaux R; Spencer MJ; Nelson SF; Miceli MC
    Sci Transl Med; 2012 Dec; 4(164):164ra160. PubMed ID: 23241744
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.